RECRUITING

Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, Small Lymphocytic TRANSCEND_CLL_004

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL. The study will include a Phase 1 part to determine the recommended dose of JCAR017 monotherapy in subjects with relapsed or refractory CLL or SLL, followed by a Phase 2 part to further assess the efficacy and safety of JCAR017 monotherapy treatment at the recommended dose. A separate Phase 1 cohort will assess the combination of JCAR017 and concurrent ibrutinib. Another separate Phase 1 cohort will assess the combination of JCAR017 and concurrent venetoclax. In all subjects, the safety, efficacy, and pharmacokinetics (PK) of JCAR017 will be evaluated.

Official Title

An Open-Label, Phase 1/2 Study of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)

Quick Facts

Study Start:2017-11-27

Study Completion:2027-11-26

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT03331198

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Diagnosis of: 1. CLL with an indication for treatment based on the Investigator's opinion and measurable disease, or 2. SLL (lymphadenopathy and/or splenomegaly and \< 5×10\^9 CD19+ CD5+ clonal B lymphocytes/L \[\< 5000/µL\] in the peripheral blood at diagnosis with measurable disease that is biopsy-proven SLL) * Subjects (other than those in the ibrutinib + JCAR017 combination therapy and DEME cohort) must have received and failed Bruton tyrosine kinase inhibitor (BTKi) treatment or have been deemed ineligible for BTKi therapy. * Subjects in the JCAR017 monotherapy cohorts must have received previous treatment as follows: 1. Monotherapy cohorts EXCEPT DEME cohort: Subjects with CLL or SLL and high-risk features must have failed at least 2 lines of prior therapy. 2. Monotherapy cohorts EXCEPT DEME cohort: Subjects with CLL or SLL and standard-risk features must have failed at least 3 lines of prior therapy. 3. DEME cohort ONLY: Subjects with relapsed or refractory CLL or SLL, irrespective of cytogenetic risk features, must have received at least 2 lines of prior therapy including a BTKi and a BCL2i. * Subjects in the ibrutinib + JCAR017 combination therapy cohort must either: 1. be receiving ibrutinib and progressing at the time of study enrollment 2. be receiving ibrutinib for at least 6 months with a response less than complete response/remission (CR) and have high-risk features as defined in inclusion criterion 5a 3. have BTK or PLCgamma2 mutations per local laboratory assessment, with or without progression on ibrutinib 4. have previously received ibrutinib and have no contraindications to restarting ibrutinib * Eastern Cooperative Oncology Group performance status of ≤ 1 * Assessed by the Investigator to have adequate bone marrow function to receive lymphodepleting chemotherapy * Adequate organ function, defined as: 1. Serum creatinine ≤ 1.5 × age-adjusted upper limit of normal (ULN) OR calculated creatinine clearance \> 30 mL/min 2. Alanine aminotransferase ≤ 5 × ULN and total bilirubin \< 2.0 mg/dL (or \< 3.0 mg/dL for subjects with Gilbert's syndrome or leukemic infiltration of the liver) 3. Adequate pulmonary function, defined as ≤ Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 dyspnea and saturated oxygen (SaO2) ≥ 92% on room air 4. Adequate cardiac function, defined as left ventricular ejection fraction ≥ 40% as assessed by echocardiogram or multiple uptake gated acquisition scan performed within 30 days prior to determination of eligibility * Subject either currently has central vascular access or is a candidate to receive central vascular access or peripheral vascular access for leukapheresis procedure. * If prior CD19-targeted therapy has been administered, subject must have CD19-positive disease confirmed by immunohistochemistry or flow cytometry since completing the prior CD19-targeted therapy. * Subjects in ibrutinib + JCAR017 combination cohort must have progressed on a BTKi and have received prior therapy with venetoclax * Subjects in venetoclax + JCAR017 combination cohort must: 1. have failed at least 1 prior line of therapy, including failed BTKi therapy or have been deemed ineligible to receive BTKi 2. be venetoclax naive (required for dose expansion) or 3. if prior venetoclax (only for dose escalation) 4. have no contraindictions to re-initiation of venetoclax based on prior intolerance and have had at least 6 months elapsed since the last dose of venetoclax, if either, best response was stable disease, or subject experienced disease progression on venetoclax, or within 6 months of venetoclax discontinuation * subjects in the venetoclax + JCAR017 combination must have hemoglobin \>=9 g/dL, absolute neutrophil count \>=500mm3 and platelets\>= 75,000/mm3, unless cytopenias are judged by investigator to be due to CLL infiltration of the bone marrow * must have diagnosis of CLL or SLL with an indication for treatment based on the investigator's opinion and measurable disease (any of the following measurable lymph nodes ≥1.5 cm in the greatest transverse diameter and/or hepatomegaly or splenomegaly) and demonstration of CLL cells in the peripheral blood by flow cytometry	* Subjects with known active central nervous system (CNS) involvement by malignancy. Those with prior CNS disease that has been effectively treated will be eligible if treatment was completed at least 3 months prior to enrollment with no evidence of symptomatic disease and stable abnormalities on repeat imaging. * History of another primary malignancy that has not been in remission for at least 2 years. (The following are exempt from the 2-year limit: nonmelanoma skin cancer, completely resected stage 1 solid tumor with low risk for recurrence, curatively treated localized prostate cancer, cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on Pap smear, and in situ breast cancer that has been completely resected.) * Subjects with Richter's transformation * Prior treatment with any gene therapy product * Active hepatitis B, active hepatitis C, or active human immunodeficiency virus (HIV) infection * Systemic fungal, bacterial, viral, or other infection that is not controlled * Presence of acute or extensive chronic graft versus host disease (GVHD) * History of any one of the following cardiovascular conditions within the past 6 months: Class III or IV heart failure as defined by the New York Heart Association (NYHA), cardiac angioplasty or stenting, myocardial infarction, unstable angina, or other clinically significant cardiac disease * History or presence of clinically relevant CNS pathology such as epilepsy, generalized seizure disorder, aphasia, stroke with current neurologic sequelae, severe brain injuries, dementia, Parkinson's disease, cerebellar disease,cerebral edema, or psychosis * Pregnant or nursing (lactating) women * Use of any of the following medications or treatments within the noted time prior to leukapheresis: 1. Alemtuzumab within 6 months prior to leukapheresis 2. Allogeneic hematopoietic stem cell transplant within 100 days prior to leukapheresis 3. Cladribine within 3 months prior to leukapheresis 4. Donor lymphocyte infusions (DLI) within 2 months prior to leukapheresis 5. Radiation including large bone marrow fields such as sternum or pelvis within 6 weeks prior to leukapheresis 6. Fludarabine within 4 weeks prior to leukapheresis 7. GVHD therapies such as calcineurin inhibitors, methotrexate or other chemotherapeutics, mycophenolate mofetil, rapamycin, or immunosuppressive antibodies (such as anti-tumor necrosis factor-α \[TNFα\], anti-interleukin-6 \[IL-6\], or anti-interleukin-6 receptor \[IL 6R\]) within 4 weeks prior to leukapheresis 8. Cyclophosphamide, ifosfamide, bendamustine, chlorambucil, or melphalan within 2 weeks prior to leukapheresis 9. Therapeutic doses of corticosteroids (defined as \> 20 mg/day prednisone or equivalent) within 7 days prior to leukapheresis 10. Anti-CD20 monoclonal antibodies within 7 days prior to leukapheresis 11. Venetoclax within 4 days prior to leukapheresis 12. Idelalisib or duvelisib within 2 days prior to leukapheresis 13. Lenalidomide or covalent and non-covalent BTKi within 1 day prior to leukapheresis 14. Experimental agents, including off-label use of approved drugs (with the exception of acalabrutinib which may be continued up to the day before leukapheresis), within 4 weeks prior to leukapheresis unless progression is documented on the experimental therapy and at least 3 half-lives have elapsed prior to leukapheresis * Uncontrolled medical, psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol, as judged by the Investigator; or subject unwillingness or inability to follow the procedures required in the protocol * Progressive vascular tumor invasion, thrombosis, or embolism * Deep vein thrombosis or embolism not managed on a stable regimen of anticoagulation * Use of any of the following medications or treatments within the noted time prior to leukapheresis lenalidomide or acalabrutinib within 1 day prior to leukapheresis experimental agents, including off-label use of approved drugs, within 4 weeks prior to leukapheresis. * Venous thrombosis or embolism requiring treatment but not managed on a stable regimen of anticoagulation * For subjects in the venetoclax + JCAR017 combination cohorts only, concomitant treatment with CYP3A moderate/strong inducers or moderate/strong inhibitors which cannot be discontinued

Inclusion Criteria

Exclusion Criteria

* Diagnosis of:
1. CLL with an indication for treatment based on the Investigator's opinion and measurable disease, or
2. SLL (lymphadenopathy and/or splenomegaly and \< 5×10\^9 CD19+ CD5+ clonal B lymphocytes/L \[\< 5000/µL\] in the peripheral blood at diagnosis with measurable disease that is biopsy-proven SLL)
* Subjects (other than those in the ibrutinib + JCAR017 combination therapy and DEME cohort) must have received and failed Bruton tyrosine kinase inhibitor (BTKi) treatment or have been deemed ineligible for BTKi therapy.
* Subjects in the JCAR017 monotherapy cohorts must have received previous treatment as follows:
1. Monotherapy cohorts EXCEPT DEME cohort: Subjects with CLL or SLL and high-risk features must have failed at least 2 lines of prior therapy.
2. Monotherapy cohorts EXCEPT DEME cohort: Subjects with CLL or SLL and standard-risk features must have failed at least 3 lines of prior therapy.
3. DEME cohort ONLY: Subjects with relapsed or refractory CLL or SLL, irrespective of cytogenetic risk features, must have received at least 2 lines of prior therapy including a BTKi and a BCL2i.
* Subjects in the ibrutinib + JCAR017 combination therapy cohort must either:
1. be receiving ibrutinib and progressing at the time of study enrollment
2. be receiving ibrutinib for at least 6 months with a response less than complete response/remission (CR) and have high-risk features as defined in inclusion criterion 5a
3. have BTK or PLCgamma2 mutations per local laboratory assessment, with or without progression on ibrutinib
4. have previously received ibrutinib and have no contraindications to restarting ibrutinib
* Eastern Cooperative Oncology Group performance status of ≤ 1
* Assessed by the Investigator to have adequate bone marrow function to receive lymphodepleting chemotherapy
* Adequate organ function, defined as:
1. Serum creatinine ≤ 1.5 × age-adjusted upper limit of normal (ULN) OR calculated creatinine clearance \> 30 mL/min
2. Alanine aminotransferase ≤ 5 × ULN and total bilirubin \< 2.0 mg/dL (or \< 3.0 mg/dL for subjects with Gilbert's syndrome or leukemic infiltration of the liver)
3. Adequate pulmonary function, defined as ≤ Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 dyspnea and saturated oxygen (SaO2) ≥ 92% on room air
4. Adequate cardiac function, defined as left ventricular ejection fraction ≥ 40% as assessed by echocardiogram or multiple uptake gated acquisition scan performed within 30 days prior to determination of eligibility
* Subject either currently has central vascular access or is a candidate to receive central vascular access or peripheral vascular access for leukapheresis procedure.
* If prior CD19-targeted therapy has been administered, subject must have CD19-positive disease confirmed by immunohistochemistry or flow cytometry since completing the prior CD19-targeted therapy.
* Subjects in ibrutinib + JCAR017 combination cohort must have progressed on a BTKi and have received prior therapy with venetoclax
* Subjects in venetoclax + JCAR017 combination cohort must:
1. have failed at least 1 prior line of therapy, including failed BTKi therapy or have been deemed ineligible to receive BTKi
2. be venetoclax naive (required for dose expansion) or
3. if prior venetoclax (only for dose escalation)
4. have no contraindictions to re-initiation of venetoclax based on prior intolerance and have had at least 6 months elapsed since the last dose of venetoclax, if either, best response was stable disease, or subject experienced disease progression on venetoclax, or within 6 months of venetoclax discontinuation
* subjects in the venetoclax + JCAR017 combination must have hemoglobin \>=9 g/dL, absolute neutrophil count \>=500mm3 and platelets\>= 75,000/mm3, unless cytopenias are judged by investigator to be due to CLL infiltration of the bone marrow
* must have diagnosis of CLL or SLL with an indication for treatment based on the investigator's opinion and measurable disease (any of the following measurable lymph nodes ≥1.5 cm in the greatest transverse diameter and/or hepatomegaly or splenomegaly) and demonstration of CLL cells in the peripheral blood by flow cytometry

* Subjects with known active central nervous system (CNS) involvement by malignancy. Those with prior CNS disease that has been effectively treated will be eligible if treatment was completed at least 3 months prior to enrollment with no evidence of symptomatic disease and stable abnormalities on repeat imaging.
* History of another primary malignancy that has not been in remission for at least 2 years. (The following are exempt from the 2-year limit: nonmelanoma skin cancer, completely resected stage 1 solid tumor with low risk for recurrence, curatively treated localized prostate cancer, cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on Pap smear, and in situ breast cancer that has been completely resected.)
* Subjects with Richter's transformation
* Prior treatment with any gene therapy product
* Active hepatitis B, active hepatitis C, or active human immunodeficiency virus (HIV) infection
* Systemic fungal, bacterial, viral, or other infection that is not controlled
* Presence of acute or extensive chronic graft versus host disease (GVHD)
* History of any one of the following cardiovascular conditions within the past 6 months: Class III or IV heart failure as defined by the New York Heart Association (NYHA), cardiac angioplasty or stenting, myocardial infarction, unstable angina, or other clinically significant cardiac disease
* History or presence of clinically relevant CNS pathology such as epilepsy, generalized seizure disorder, aphasia, stroke with current neurologic sequelae, severe brain injuries, dementia, Parkinson's disease, cerebellar disease,cerebral edema, or psychosis
* Pregnant or nursing (lactating) women
* Use of any of the following medications or treatments within the noted time prior to leukapheresis:
1. Alemtuzumab within 6 months prior to leukapheresis
2. Allogeneic hematopoietic stem cell transplant within 100 days prior to leukapheresis
3. Cladribine within 3 months prior to leukapheresis
4. Donor lymphocyte infusions (DLI) within 2 months prior to leukapheresis
5. Radiation including large bone marrow fields such as sternum or pelvis within 6 weeks prior to leukapheresis
6. Fludarabine within 4 weeks prior to leukapheresis
7. GVHD therapies such as calcineurin inhibitors, methotrexate or other chemotherapeutics, mycophenolate mofetil, rapamycin, or immunosuppressive antibodies (such as anti-tumor necrosis factor-α \[TNFα\], anti-interleukin-6 \[IL-6\], or anti-interleukin-6 receptor \[IL 6R\]) within 4 weeks prior to leukapheresis
8. Cyclophosphamide, ifosfamide, bendamustine, chlorambucil, or melphalan within 2 weeks prior to leukapheresis
9. Therapeutic doses of corticosteroids (defined as \> 20 mg/day prednisone or equivalent) within 7 days prior to leukapheresis
10. Anti-CD20 monoclonal antibodies within 7 days prior to leukapheresis
11. Venetoclax within 4 days prior to leukapheresis
12. Idelalisib or duvelisib within 2 days prior to leukapheresis
13. Lenalidomide or covalent and non-covalent BTKi within 1 day prior to leukapheresis
14. Experimental agents, including off-label use of approved drugs (with the exception of acalabrutinib which may be continued up to the day before leukapheresis), within 4 weeks prior to leukapheresis unless progression is documented on the experimental therapy and at least 3 half-lives have elapsed prior to leukapheresis
* Uncontrolled medical, psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol, as judged by the Investigator; or subject unwillingness or inability to follow the procedures required in the protocol
* Progressive vascular tumor invasion, thrombosis, or embolism
* Deep vein thrombosis or embolism not managed on a stable regimen of anticoagulation
* Use of any of the following medications or treatments within the noted time prior to leukapheresis lenalidomide or acalabrutinib within 1 day prior to leukapheresis experimental agents, including off-label use of approved drugs, within 4 weeks prior to leukapheresis.
* Venous thrombosis or embolism requiring treatment but not managed on a stable regimen of anticoagulation
* For subjects in the venetoclax + JCAR017 combination cohorts only, concomitant treatment with CYP3A moderate/strong inducers or moderate/strong inhibitors which cannot be discontinued

Contacts and Locations

Study Contact

BMS Study Connect Contact Center www.BMSStudyConnect.com

CONTACT

855-907-3286

Clinical.Trials@bms.com

First line of the email MUST contain the NCT# and Site #.

CONTACT

Principal Investigator

Bristol-Myers Squibb

STUDY_DIRECTOR

Bristol-Myers Squibb

Study Locations (Sites)

Local Institution - 0006

Birmingham, Alabama, 35294

United States

University of Alabama at Birmingham

Birmingham, Alabama, 35294

United States

Banner MD Anderson Cancer Center

Gilbert, Arizona, 85234

United States

Banner MD Anderson Cancer Center

Gilbert, Arizona, 85234

United States

City Of Hope

Duarte, California, 91010-301

United States

City of Hope

Duarte, California, 91010

United States

UC San Diego Moores Cancer Center

La Jolla, California, 92093

United States

University Of California San Diego Moores Cancer Center

La Jolla, California, 92093

United States

Local Institution - 0059

Los Angeles, California, 90095

United States

University of California, Los Angeles

Los Angeles, California, 90095

United States

Local Institution - 0010

San Francisco, California, 94143

United States

University of California, San Francisco

San Francisco, California, 94143

United States

Local Institution - 0111

Denver, Colorado, 80218

United States

Local Institution - 0110

Newark, Delaware, 19713

United States

Georgetown University Medical Center

Washington, District of Columbia, 20007

United States

Local Institution - 0085

Washington, District of Columbia, 20007

United States

Local Institution - 0080

Jacksonville, Florida, 32224

United States

Mayo Clinic

Jacksonville, Florida, 32224

United States

Local Institution - 0104

Atlanta, Georgia, 30322

United States

Local Institution - 0019

Atlanta, Georgia, 30342

United States

The Blood and Marrow Transplant Group of Georgia (BMTGA)

Atlanta, Georgia, 30342

United States

Northwestern Memorial Hospital

Chicago, Illinois, 60611

United States

Northwestern University

Chicago, Illinois, 60611

United States

University of Chicago Medical Center

Chicago, Illinois, 60637

United States

University Of Chicago Medical Center

Chicago, Illinois, 60637

United States

Local Institution - 0105

Indianapolis, Indiana, 46237

United States

Local Institution - 0107

Wichita, Kansas, 67124

United States

Norton Healthcare - Norton Cancer Institute

Louisville, Kentucky, 40202

United States

Local Institution - 0005

Boston, Massachusetts, 02114

United States

Massachusetts General Hospital

Boston, Massachusetts, 02114

United States

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215

United States

Local Institution - 0015

Boston, Massachusetts, 02215

United States

University of Michigan Comprehensive Cancer Center

Ann Arbor, Michigan, 48109-5362

United States

University Of Michigan Comprehensive Cancer Center

Ann Arbor, Michigan, 48109

United States

Barbara Ann Karmanos Cancer Institute

Detroit, Michigan, 48201

United States

Local Institution - 0062

Detroit, Michigan, 48201

United States

Local Institution - 0109

Detroit, Michigan, 48202

United States

Mayo Clinic

Rochester, Minnesota, 55905

United States

Mayo Clinic

Rochester, Minnesota, 55905

United States

University of Nebraska Medical Center

Omaha, Nebraska, 68198

United States

University Of Nebraska Medical Center

Omaha, Nebraska, 68198

United States

Local Institution - 0001

Basking Ridge, New Jersey, 07920

United States

John Theurer Cancer Center

Hackensack, New Jersey, 07601-2191

United States

Hackensack University Medical Center

Hackensack, New Jersey, 07601

United States

Local Institution - 0106

Morristown, New Jersey, 07960

United States

Local Institution - 0077

New Brunswick, New Jersey, 08903

United States

Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, 08903

United States

Local Institution - 0035

New York, New York, 10021

United States

Columbia University Medical Center

New York, New York, 10032

United States

Local Institution - 0026

New York, New York, 10032

United States

Weill Cornell Medical College

New York, New York, 10065

United States

Local Institution - 0089

Stony Brook, New York, 11794-8160

United States

Duke University Medical Center

Durham, North Carolina, 27705

United States

Duke University Medical Center

Durham, North Carolina, 27710

United States

University Hospitals Seidman Cancer Center (Case Western)

Cleveland, Ohio, 44106-5061

United States

University Hospitals Cleveland Medical Center

Cleveland, Ohio, 44106

United States

Local Institution - 0031

Columbus, Ohio, 43210

United States

University of Oklahoma Health Sciences Center (Stephenson Cancer Center)

Oklahoma City, Oklahoma, 73104

United States

University of Oklahoma Peggy and Charles Stephenson Cancer Center

Oklahoma City, Oklahoma, 73104

United States

Local Institution - 0098

Eugene, Oregon, 97401

United States

University of Pennsylvania - Perelman Center for Advanced Medicine

Philadelphia, Pennsylvania, 19104

United States

University of Pennsylvania Perelman Center for Advanced Medicine

Philadelphia, Pennsylvania, 19104

United States

Thomas Jefferson University - Clinical Research Institute

Philadelphia, Pennsylvania, 19107

United States

Thomas Jefferson University

Philadelphia, Pennsylvania, 19107

United States

Local Institution - 0029

Pittsburgh, Pennsylvania, 15232

United States

UPMC Hillman Cancer Center

Pittsburgh, Pennsylvania, 15232

United States

Baylor University Medical Center

Dallas, Texas, 75246

United States

Local Institution - 0083

Dallas, Texas, 75390

United States

University of Texas Southwestern Medical Center

Dallas, Texas, 75390

United States

Local Institution - 0079

Dallas, Texas, 75426

United States

The University of Texas - MD Anderson Cancer Center

Houston, Texas, 77030

United States

The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030

United States

Huntsman Cancer Institute

Salt Lake City, Utah, 84112

United States

Local Institution - 0028

Salt Lake City, Utah, 84112

United States

Local Institution - 0113

Charlottesville, Virginia, 22903

United States

Local Institution - 0087

Richmond, Virginia, 23298

United States

Virginia Commonwealth University

Richmond, Virginia, 23298

United States

Fred Hutchinson Cancer Research Center

Seattle, Washington, 98109

United States

Local Institution - 0018

Seattle, Washington, 98109

United States

Froedtert Hospital BMT Medical College of Wisconsin

Milwaukee, Wisconsin, 53226

United States

Medical College of Wisconsin

Milwaukee, Wisconsin, 53226

United States

Collaborators and Investigators

Sponsor: Juno Therapeutics, a Subsidiary of Celgene

Bristol-Myers Squibb, STUDY_DIRECTOR, Bristol-Myers Squibb

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2017-11-27

Study Completion Date2027-11-26

Study Record Updates

Study Start Date2017-11-27

Study Completion Date2027-11-26

Terms related to this study

Keywords Provided by Researchers

TRANSCEND_CLL_004

Additional Relevant MeSH Terms

Leukemia, Lymphocytic, Chronic, B-Cell
Lymphoma, Small Lymphocytic